title: [Cardiovascular risk assessment and intervention in HIV-infected patients].
abstract: Because of the increased cardiovascular risk (CVR) in HIV-positive patients, preventive measures are essential, requiring algorithms for risk estimation, such as the Framingham risk equation, the Prospective Cardiovascular Munster Study (PROCAM) algorithm and the Systematic Coronary Risk Evaluation (SCORE) chart. Classical cardiovascular risk factors (CVRF) are closely related to CVR in HIV-infected patients but whether this risk is comparable to that in the general population is unknown. Therefore, these algorithms probably underestimate the risk in these patients. Currently, application of the same strategies as those used in the general population is recommended, without forgetting the specific characteristics of HIV positive patients or the importance of their inflammatory status, which can accelerate the development of arteriosclerosis and lead to an increase in cardiovascular morbidity and mortality. Therefore, in addition to traditional CVRF, biological markers of inflammation could help to identify the patients most at risk of a cardiovascular event. These markers, as well as the diverse techniques for assessment of subclinical atherosclerosis that could help in the early identification of at-risk patients, are reviewed in the present study. Lifestyle changes (healthy diet, smoking cessation, maintaining a healthy weight and daily physical exercise) reduce the probability of a coronary event by up to 80% in the general population. Traditional therapeutic measures (dyslipidemia, hypertension, diabetes mellitus) and those specific to HIV infection (viral suppression, discontinuous treatment, etc.) are reviewed.
authors.affiliation: Servicio de Medicina Interna, Hospital de Sant Pau i Santa Tecla, Tarragona, España.
authors.forename: Sebastián
authors.initials: S
authors.lastname: Hernández
authors.forename: Magdalena
authors.initials: M
authors.lastname: Vidal
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
mesh_terms: D000328:Adult; D000465:Algorithms; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology; D015331:Cohort Studies; D015897:Comorbidity; D004198:Disease Susceptibility; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology / Q000628:therapy; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology / Q000628:therapy; D012307:Risk Factors; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D000074606:Smoking Prevention; D019851:Thrombophilia / Q000097:blood / Q000453:epidemiology
chemical_list: D019380:Anti-HIV Agents